Navigation Links
LightPath Technologies Provides Quarterly Update on Infrared Initiatives
Date:10/31/2012

ORLANDO, Fla., Oct. 31, 2012 /PRNewswire/ -- LightPath Technologies, Inc. (NASDAQ: LPTH) ("LightPath", the "Company" or "we"), a global manufacturer, distributor and integrator of patented optical components and high-level assemblies, today provided an update to shareholders on its progress with its infrared lens initiatives.  

(Logo: http://photos.prnewswire.com/prnh/20120202/FL45310LOGO )

LightPath continues to develop its thermal imaging business and is currently in the later stages of upgrading manufacturing capabilities at its Orlando factory to support the anticipated growth in its thermal infrared product lines. Sales and technical teams have been in contact with many large OEMs who purchase infrared optics in this space and LightPath has received initial orders from three such OEMs for prototypes of optical assemblies for their respective thermal imaging systems. LightPath's optics provide significant material cost advantages for its customers through the use of chalcogenide glass compared to the materials that are currently in use today for such systems. LightPath continues to see significant growth opportunities for this business and expects significant orders from these and other customers in the second half of fiscal 2013. 

In addition, the infrared development program with Raytheon Vision Systems continues to progress and work is now shifting from producing initial prototypes to developing the necessary production-scale cost reductions to meet the program's cost and performance goals. With a substantial portion of the investment phase now completed, core manufacturing techniques and resources are now in place with significant improvements having been made in the protective coatings for the lenses. As the cost reductions are developed from this work, they are being implemented into LightPath's proprietary process.

Jim Gaynor, President and Chief Executive Officer of LightPath, commented, "We are excited by the growing acceptance of the infrared products we offer as we continue to successfully penetrate this $150 million addressable market serving a diverse customer base. In particular, we see our infrared business being driven by demand for our quantum cascade laser lenses, with interest from customers in various subsectors, such as infrared countermeasures, gas analysis and spectroscopy."

About LightPath TechnologiesLightPath manufactures optical products including precision molded aspheric optics, GRADIUM® glass products, proprietary collimator assemblies, laser components utilizing proprietary automation technology, higher-level assemblies and packing solutions. The Company's products are used in various markets, including industrial, medical, defense, test and measurement and telecommunications. LightPath has a strong patent portfolio that has been granted or licensed to it in these fields. For more information visit www.lightpath.com.

Forward-Looking StatementsThis news release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our ability to expand our presence in certain markets, future sales growth, continuing reductions in cash usage and implementation of new distribution channels. This information may involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, factors detailed by LightPath Technologies, Inc. in its public filings with the Securities and Exchange Commission. Except as required under the federal securities laws and the rules and regulations of the Securities and Exchange Commission, we do not have any intention or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.Contacts: Jim Gaynor, President & CEO

Dorothy Cipolla, CFOLightPath Technologies, Inc.

LightPath Technologies, Inc. Tel: 407-382-4003

Tel: 407-382-4003 x305Email: jgaynor@lightpath.com 

Email: dcipolla@lightpath.com  Web: www.lightpath.com 

Web: www.lightpath.comBrett Maas, Managing Partner Hayden IR Tel: 646-536-7331 Email: Brett@haydenir.com Web: www.haydenir.com
'/>"/>

SOURCE LightPath Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global eClinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies: MarketResearchReports.Biz
2. Harvest Technologies Corporation reicht Patentverletzungsklage gegen ThermoGenesis Corporation ein
3. Harvest Technologies Corporation Files Patent Infringement Complaint against ThermoGenesis Corporation
4. Pathogenica and Life Technologies EMEA Partner to Control Hospital Acquired Infections
5. DiFUSION Technologies Announces Breakthrough Medical Polymer
6. Top 10 Drug Delivery Technologies (2010 - 2015)
7. Lifeline Biotechnologies Receives Third Software Patent
8. Creation Technologies Expands Its China Manufacturing Footprint
9. Life Technologies to Partner with Bristol-Myers Squibb for Companion Diagnostics Development
10. Life Technologies Begins Shipping Ion Proton System
11. Terso Solutions partners with Champion Medical Technologies to offer fully automated tracking of Tissue and Implantable Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds ... the launch of a new DRTV campaign with Belly Bands. , Having a dog ... from sprays to puppy pads and find nothing works, get Belly Bands, the ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 ... ... today announced the availability of the company's lighter, sleeker next generation LYNX VR ... assembly plant. , Improvements in design and manufacturing not only reduce the ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... ... 05, 2016 , ... After years as an active staff surgeon and having ... surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at ... term as chief and began a second three-year term in January of 2016. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
Breaking Medicine News(10 mins):